查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1370927

營養保健品 CDMO 市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會與預測，按劑型、服務、公司規模、地區、競爭細分

Nutraceuticals CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Dosage Form, By Service, By Company Size, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球營養保健品CDMO 市場在2022 年達到340.9 億美元的估值，預計將以7.87% 的年複合成長率實現令人印象深刻的成長，預計到2028 年將達到534.5 億美元。營養保健品CDMO 代表合約開發和製造組織，指為營養保健品公司提供開發和製造服務的公司。營養保健品是結合食品和藥物成分的產品，提供基本營養以外的健康益處。另一方面，CDMO 則透過協助其產品的開發、製造，有時甚至行銷來滿足製藥、生物技術和營養保健品公司的需求。 CDMO 提供專業知識、設施和資源，在產品生命週期的各個階段（從研發到製造和分銷）為客戶提供支援。

主要市場促進因素

  • 1.營養保健品需求的成長推動市場成長：營養保健品需求的激增大大推動了全球保健品 CDMO 市場的擴張。隨著消費者對營養保健品的興趣持續上升，對創新和差異化產品的需求不斷增加。營養保健品公司通常需要專業知識來開發和配製符合消費者偏好和健康要求的新產品。營養保健品 CDMO 提供研發能力，協助公司創造新穎的配方，在市場上提供更廣泛的營養保健產品。對營養保健品的高需求需要擴大生產能力，而營養保健品 CDMO 擁有有效生產大量產品的基礎設施和專業知識，以滿足成熟和新興保健品品牌的需求。
市場概況
預測期 2024-2028
2022 年市場規模 340.9億美元
2028 年市場規模 534.5億美元
2023-2028 年年複合成長率 7.87%
成長最快的細分市場 片劑和膠囊
最大的市場 北美洲
  • 2.慢性病盛行率的增加推動市場成長：慢性病發生率的上昇在推動全球營養藥品 CDMO 市場方面發揮重要作用。心血管疾病、糖尿病、肥胖和神經退化性疾病等慢性疾病通常與生活方式因素和不良飲食選擇有關。消費者越來越積極主動地關注自己的健康，尋求預防措施來降低慢性病的風險。營養保健品具有潛在的健康益處，被視為預防性醫療策略的一部分。營養藥品 CDMO 在開發和製造這些產品以滿足不斷成長的需求方面發揮關鍵作用。營養保健品因其在管理慢性疾病方面的潛在治療益處而日益得到認可，營養保健品 CDMO 與製藥和營養保健品公司合作，開發針對特定慢性病的專門產品。
  • 3.研發進步推動市場成長：研發（R＆D）的進步大大促進了全球營養藥品 CDMO 市場的成長。研發進步導致營養保健品的新穎成分、配方和輸送系統的發現。營養藥品 CDMO 與營養藥品公司合作，將這些創新轉化為可上市的產品。研發進步也使人們更深入了解各種營養素和生物活性化合物的健康益處和作用機制。營養保健品 CDMO 促進科學研究與產品開發的整合，使公司能夠創建經過臨床驗證和證實的實證營養保健品。這些進步使人們能夠更好地了解營養保健品可以解決的特定健康問題和狀況，從而開發出有針對性的健康解決方案。此外，研發也根據遺傳、生活方式和健康狀況增強了對個人營養需求的了解，從而能夠創造出個人化的營養解決方案。

主要市場挑戰

  • 1.品質控制和保證：由於確保一致的產品品質和安全性的複雜性和關鍵性，品質控制和保證對全球營養藥品 CDMO 市場構成了重大挑戰。營養保健品須遵守監管標準，以確保其安全性、有效性和準確的標籤。遵守不同地區多樣化且不斷變化的法規可能非常複雜且耗時。營養藥品 CDMO 必須跟上不斷變化的法規並相應地調整其流程。確保不同批次的品質和效力一致具有挑戰性，特別是對於含有多種活性成分的複雜配方。成分特性的變化，例如易受季節變化影響的天然成分，可能會使過程複雜化。營養藥品 CDMO 必須仔細選擇供應商並建立嚴格的品質標準，以盡量減少變異。
  • 2.成分採購和供應鏈中斷：成分採購和供應鏈中斷可能對全球營養藥品 CDMO 市場帶來重大挑戰。成分供應商的可靠性和一致性可能會有所不同，從而影響營養保健品配方的基本成分的品質和可用性。許多營養保健品成分均源自天然來源，且可用性和品質可能會受到季節性變化的影響，從而影響產品配方的一致性。地緣政治因素、貿易限制和自然災害可能會擾亂供應鏈並影響原料的供應。確保原料的品質和真實性至關重要，需要嚴格的測試和驗證流程。
  • 3.環境永續性：環境永續性對全球營養藥品 CDMO 市場提出了重大挑戰，因為該產業尋求平衡業務成長與負責任的環境實踐。營養保健成分通常會產生生態影響，例如森林砍伐和棲息地破壞，並可能威脅當地的生態系統和生物多樣性。該行業還產生廢物，包括包裝材料和副產品。透過永續採購實踐、負責任的廢棄物管理和環保包裝替代品來減少對環境的影響至關重要。此外，製造過程中的能源消耗和溫室氣體排放必須透過節能技術和再生能源來解決。

主要市場趨勢

  • 1.個人化營養的興起：個人化營養是全球營養保健品 CDMO 市場的重要趨勢，影響營養保健品的開發、配製和製造方式。這一趨勢涉及根據個人獨特的健康需求、基因組成、生活方式和偏好量身定做飲食和補充劑建議。營養藥品 CDMO 在開發符合每個消費者俱體要求的定製配方方面發揮關鍵作用。這一趨勢要求 CDMO 具備專業知識，能夠創造出多樣化且靈活的配方，並可根據個人因素進行調整。個人化營養依賴於全面的健康評估、生物標記分析和基因測試來確定個人的營養需求，CDMO 可以與測試實驗室和醫療保健專業人員合作，將這些資料涵蓋配方過程。
  • 2.劑型主導：2022年，片劑和膠囊領域主導營養藥品CDMO市場，預計將持續擴大。片劑和膠囊因其方便、易於食用和精確的劑量能力而成為流行的劑型。它們為封閉成分提供穩定性和保護，免受環境因素的影響並有助於延長保存期限。預計 2023 年至 2030 年該細分市場將經歷最高的年複合成長率(CAGR)。
  • 3.製造和包裝服務：製造和包裝服務在營養藥品 CDMO 市場中至關重要。製造服務包括營養保健品的生產，而包裝服務則涉及零售或分銷的設計、標籤和包裝。有效的包裝對於產品差異化、消費者溝通和法規遵循至關重要。
  • 4.中型 CDMO：中型營養保健品 CDMO 敏捷且反應靈敏，提供個人化服務並建立強大的客戶關係。他們通常專注於營養保健品產業，在配方、製造、監管合規性和市場趨勢方面擁有深厚的專業知識。中型 CDMO 以創新和適應性而聞名，能夠快速響應市場變化並推出

獨特的營養保健品。

  • 5.北美主導地位：北美，特別是美國，由於成熟的市場、消費者對膳食補充劑的強烈接受度以及完善的監管框架，在全球營養保健品CDMO市場中處於領先地位。北美消費者對健康和保健的日益關注推動了對營養保健產品的需求，從而導致對 CDMO 服務的更大需求。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球保健品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按劑型（片劑和膠囊、粉末、軟膠囊、其他）
    • 按服務（產品配方和開發、製造和包裝、研究與開發 (R&D)、法規合規性、其他）
    • 依公司規模（小型公司、中型公司、大型公司）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美營養藥品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依劑型分類
    • 按服務
    • 按公司規模
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲營養藥品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依劑型分類
    • 按服務
    • 按公司規模
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太營養保健品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依劑型分類
    • 按服務
    • 按公司規模
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲營養藥品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依劑型分類
    • 按服務
    • 按公司規模
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲營養藥品 CDMO 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依劑型分類
    • 按服務
    • 按公司規模
    • 按國家/地區
  • MEA：國家分析
    • 南非營養保健品 CDMO
    • 沙烏地阿拉伯營養保健品 CDMO
    • 阿拉伯聯合大公國營養保健品 CDMO

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Catalent Inc.
    • Lonza Group AG
    • NUTRASCIENCE LABS Inc
    • Robinson Pharma, Inc.
    • Health Wright Products, Inc.
    • Innovations in Nutrition + Wellness
    • INPHARMA SpA
    • Aenova Group
    • NutraPakUSA
    • SFI Health Pty Ltd.

第 16 章：策略建議

簡介目錄
Product Code: 17092

The Global Nutraceuticals CDMO Market achieved a valuation of USD 34.09 Billion in 2022 and is poised for impressive growth at a projected CAGR of 7.87% and is expected to reach USD 53.45 Billion by 2028. Nutraceuticals CDMO, which stands for Contract Development and Manufacturing Organization, refers to companies that provide development and manufacturing services to nutraceutical firms. Nutraceuticals are products that combine food and pharmaceutical components, offering health benefits beyond basic nutrition. CDMOs, on the other hand, cater to pharmaceutical, biotechnology, and nutraceutical companies by assisting in the development, manufacturing, and occasionally even marketing of their products. CDMOs bring specialized expertise, facilities, and resources to support clients across various stages of the product lifecycle, from research and development to manufacturing and distribution.

Key Market Drivers

  • 1. Growing Demand for Nutraceutical Products Drives Market Growth: The surging demand for nutraceutical products significantly fuels the expansion of the Global Nutraceutical CDMO market. As consumer interest in nutraceuticals continues to rise, there's a heightened need for innovative and differentiated products. Nutraceutical companies often require specialized expertise to develop and formulate new products that align with consumer preferences and health requirements. Nutraceutical CDMOs offer research and development capabilities to assist companies in creating novel formulations, leading to a more extensive variety of nutraceutical products in the market. The high demand for nutraceutical products necessitates the scaling up of manufacturing capacities, and Nutraceutical CDMOs have the infrastructure and expertise to efficiently produce larger quantities of products, catering to both established and emerging nutraceutical brands.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 34.09 Billion
Market Size 2028USD 53.45 Billion
CAGR 2023-20287.87%
Fastest Growing SegmentTablets & Capsules
Largest MarketNorth America
  • 2. Increasing Prevalence of Chronic Diseases Drives Market Growth: The rising incidence of chronic diseases plays a significant role in propelling the Global Nutraceutical CDMO market. Chronic diseases such as cardiovascular diseases, diabetes, obesity, and neurodegenerative disorders are often linked to lifestyle factors and poor dietary choices. Consumers are increasingly proactive about their health, seeking preventive measures to mitigate the risk of chronic diseases. Nutraceutical products, with their potential health benefits, are being viewed as part of preventive healthcare strategies. Nutraceutical CDMOs play a pivotal role in developing and manufacturing these products to meet the growing demand. Nutraceuticals are increasingly recognized for their potential therapeutic benefits in managing chronic diseases, and Nutraceutical CDMOs collaborate with pharmaceutical and nutraceutical companies to create specialized products targeting specific chronic conditions.
  • 3. Advancements in Research and Development Drive Market Growth: Progress in research and development (R&D) significantly contributes to the growth of the Global Nutraceutical CDMO market. R&D advancements lead to the discovery of novel ingredients, formulations, and delivery systems for nutraceutical products. Nutraceutical CDMOs collaborate with nutraceutical companies to translate these innovations into market-ready products. R&D advancements also result in a deeper understanding of the health benefits and mechanisms of action of various nutrients and bioactive compounds. Nutraceutical CDMOs facilitate the integration of scientific research into product development, enabling companies to create evidence-based nutraceuticals that are clinically validated and substantiated. These advancements allow for a better understanding of specific health concerns and conditions that nutraceuticals can address, leading to the development of targeted health solutions. Additionally, R&D enhances knowledge of individual nutritional needs based on genetics, lifestyle, and health status, enabling the creation of personalized nutrition solutions.

Key Market Challenges

  • 1. Quality Control and Assurance: Quality control and assurance pose significant challenges to the Global Nutraceutical CDMO market due to the complexity and critical nature of ensuring consistent product quality and safety. Nutraceutical products are subject to regulatory standards that ensure their safety, efficacy, and accurate labeling. Compliance with diverse and evolving regulations in different regions can be complex and time-consuming. Nutraceutical CDMOs must stay up-to-date with changing regulations and adapt their processes accordingly. Ensuring consistent quality and potency across batches is challenging, particularly for complex formulations containing multiple active ingredients. Variability in ingredient characteristics, such as natural ingredients susceptible to seasonal variations, can complicate the process. Nutraceutical CDMOs must carefully select suppliers and establish stringent quality standards to minimize variability.
  • 2. Ingredient Sourcing and Supply Chain Disruptions: Ingredient sourcing and supply chain disruptions can present significant challenges to the Global Nutraceutical CDMO market. The reliability and consistency of ingredient suppliers can vary, affecting the quality and availability of essential components for nutraceutical formulations. Many nutraceutical ingredients are derived from natural sources and may be subject to seasonal variations in availability and quality, impacting consistent product formulations. Geopolitical factors, trade restrictions, and natural disasters can disrupt the supply chain and impact ingredient availability. Ensuring the quality and authenticity of sourced ingredients is crucial, requiring rigorous testing and verification processes.
  • 3. Environmental Sustainability: Environmental sustainability poses a significant challenge to the Global Nutraceutical CDMO market as the industry seeks to balance business growth with responsible environmental practices. Nutraceutical ingredients often have ecological impacts, such as deforestation and habitat destruction, and may threaten local ecosystems and biodiversity. The industry also generates waste, including packaging materials and byproducts. Reducing environmental impact through sustainable sourcing practices, responsible waste management, and eco-friendly packaging alternatives is essential. Additionally, energy consumption and greenhouse gas emissions from manufacturing processes must be addressed through energy-efficient technologies and renewable energy sources.

Key Market Trends

  • 1. Rise of Personalized Nutrition: Personalized nutrition is a significant trend in the Global Nutraceutical CDMO market, influencing how nutraceutical products are developed, formulated, and manufactured. This trend involves tailoring dietary and supplement recommendations to an individual's unique health needs, genetic makeup, lifestyle, and preferences. Nutraceutical CDMOs play a critical role in developing customized formulations that align with the specific requirements of each consumer. This trend requires CDMOs to possess the expertise to create diverse and flexible formulations that can be adjusted based on individual factors. Personalized nutrition relies on comprehensive health assessments, biomarker analysis, and genetic testing to determine an individual's nutritional needs, and CDMOs may collaborate with testing laboratories and healthcare professionals to incorporate these data into the formulation process.
  • 2. Dosage Form Dominance: In 2022, the tablets and capsules segment dominated the Nutraceuticals CDMO market and is expected to continue expanding. Tablets and capsules are popular dosage forms due to their convenience, ease of consumption, and precise dosing capabilities. They offer stability and protection for enclosed ingredients, safeguarding against environmental factors and contributing to longer shelf life. This segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.
  • 3. Manufacturing and Packaging Services: Manufacturing and packaging services are pivotal in the Nutraceuticals CDMO market. Manufacturing services encompass the production of nutraceutical products, while packaging services involve design, labeling, and packaging for retail or distribution. Effective packaging is crucial for product differentiation, consumer communication, and regulatory compliance.
  • 4. Mid-Size CDMOs: Mid-size nutraceutical CDMOs are agile and responsive, offering personalized services and building strong client relationships. They often specialize exclusively in the nutraceutical industry, enabling deep expertise in formulation, manufacturing, regulatory compliance, and market trends. Mid-size CDMOs are known for innovation and adaptability, quickly responding to market shifts and introducing

unique nutraceutical products.

  • 5. North America Dominance: North America, particularly the United States, leads the Global Nutraceuticals CDMO Market due to a mature market, strong consumer acceptance of dietary supplements, and well-established regulatory frameworks. North American consumers' increasing focus on health and wellness drives the demand for nutraceutical products, leading to a greater need for CDMO services.

Key Market Players

  • Catalent Inc.
  • Lonza Group AG
  • NUTRASCIENCE LABS Inc
  • Robinson Pharma, Inc.
  • Health Wright Products, Inc.
  • Innovations in Nutrition + Wellness
  • INPHARMA S.p.A.
  • Aenova Group
  • NutraPakUSA
  • SFI Health Pty Ltd.

Report Scope:

In this report, the Global Nutraceuticals CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nutraceuticals CDMO Market, By Dosage Form:

  • Tablets & Capsules
  • Powder
  • Softgel
  • Others

Nutraceuticals CDMO Market, By Service:

  • Product Formulation and Development
  • Manufacturing and Packaging
  • Research & Development (R&D)
  • Regulatory Compliance
  • Others

Nutraceuticals CDMO Market, By Company Size:

  • Small Companies
  • Mid-Sized Companies
  • Large Companies

Global Nutraceuticals CDMO Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Nutraceuticals CDMO Market.

Available Customizations:

  • Global Nutraceuticals CDMO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nutraceuticals CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Dosage Form (Tablets & Capsules, Powder, Softgel, Others)
    • 5.2.2. By Service (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others)
    • 5.2.3. By Company Size (Small Companies, Mid-Sized Companies, Large Companies)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Nutraceuticals CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Dosage Form
    • 6.2.2. By Service
    • 6.2.3. By Company Size
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nutraceuticals CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value Service
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Dosage Form
        • 6.3.1.2.2. By Service
        • 6.3.1.2.3. By Company Size
    • 6.3.2. Mexico Nutraceuticals CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value Service
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Dosage Form
        • 6.3.2.2.2. By Service
        • 6.3.2.2.3. By Company Size
    • 6.3.3. Canada Nutraceuticals CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value Service
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Dosage Form
        • 6.3.3.2.2. By Service
        • 6.3.3.2.3. By Company Size

7. Europe Nutraceuticals CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Dosage Form
    • 7.2.2. By Service
    • 7.2.3. By Company Size
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Nutraceuticals CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value Service
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Dosage Form
        • 7.3.1.2.2. By Service
        • 7.3.1.2.3. By Company Size
    • 7.3.2. Germany Nutraceuticals CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value Service
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Dosage Form
        • 7.3.2.2.2. By Service
        • 7.3.2.2.3. By Company Size
    • 7.3.3. United Kingdom Nutraceuticals CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value Service
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Dosage Form
        • 7.3.3.2.2. By Service
        • 7.3.3.2.3. By Company Size
    • 7.3.4. Italy Nutraceuticals CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value Service
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Dosage Form
        • 7.3.4.2.2. By Service
        • 7.3.4.2.3. By Company Size
    • 7.3.5. Spain Nutraceuticals CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value Service
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Dosage Form
        • 7.3.5.2.2. By Service
        • 7.3.5.2.3. By Company Size

8. Asia-Pacific Nutraceuticals CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Dosage Form
    • 8.2.2. By Service
    • 8.2.3. By Company Size
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Nutraceuticals CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value Service
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Dosage Form
        • 8.3.1.2.2. By Service
        • 8.3.1.2.3. By Company Size
    • 8.3.2. India Nutraceuticals CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value Service
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Dosage Form
        • 8.3.2.2.2. By Service
        • 8.3.2.2.3. By Company Size
    • 8.3.3. South Korea Nutraceuticals CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value Service
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Dosage Form
        • 8.3.3.2.2. By Service
        • 8.3.3.2.3. By Company Size
    • 8.3.4. Japan Nutraceuticals CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value Service
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Dosage Form
        • 8.3.4.2.2. By Service
        • 8.3.4.2.3. By Company Size
    • 8.3.5. Australia Nutraceuticals CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value Service
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Dosage Form
        • 8.3.5.2.2. By Service
        • 8.3.5.2.3. By Company Size

9. South America Nutraceuticals CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Dosage Form
    • 9.2.2. By Service
    • 9.2.3. By Company Size
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Nutraceuticals CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value Service
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Dosage Form
        • 9.3.1.2.2. By Service
        • 9.3.1.2.3. By Company Size
    • 9.3.2. Argentina Nutraceuticals CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value Service
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Dosage Form
        • 9.3.2.2.2. By Service
        • 9.3.2.2.3. By Company Size
    • 9.3.3. Colombia Nutraceuticals CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value Service
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Dosage Form
        • 9.3.3.2.2. By Service
        • 9.3.3.2.3. By Company Size

10. Middle East and Africa Nutraceuticals CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Dosage Form
    • 10.2.2. By Service
    • 10.2.3. By Company Size
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Nutraceuticals CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value Service
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Dosage Form
        • 10.3.1.2.2. By Service
        • 10.3.1.2.3. By Company Size
    • 10.3.2. Saudi Arabia Nutraceuticals CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value Service
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Dosage Form
        • 10.3.2.2.2. By Service
        • 10.3.2.2.3. By Company Size
    • 10.3.3. UAE Nutraceuticals CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value Service
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Dosage Form
        • 10.3.3.2.2. By Service
        • 10.3.3.2.3. By Company Size

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Catalent Inc.
    • 15.6.2. Lonza Group AG
    • 15.6.3. NUTRASCIENCE LABS Inc
    • 15.6.4. Robinson Pharma, Inc.
    • 15.6.5. Health Wright Products, Inc.
    • 15.6.6. Innovations in Nutrition + Wellness
    • 15.6.7. INPHARMA S.p.A.
    • 15.6.8. Aenova Group
    • 15.6.9. NutraPakUSA
    • 15.6.10. SFI Health Pty Ltd.

16. Strategic Recommendations